Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550876 | 1.00 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL7552747 | 0.96 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7551350 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7553594 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7551356 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7553588 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7546981 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7546976 | 0.95 | CCKBR (0.65) | CCKBRCCKAR | |
| SCHEMBL7549969 | 0.91 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL7549962 | 0.91 | CCKBR (0.61) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885CCKAR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.